DRG uses cookies to improve your experience on this website. Some of the cookies we use are essential for parts of the website to operate. Please be aware that if you continue without changing your cookie settings, you consent to this. For more information on our use of cookies, please review our cookie policy.

Research & Reports

Searching in Biopharma (1575)

TreatmentTrends: Malignant Melanoma (EU) 2013

TreatmentTrends®: Malignant Melanoma (E.U.) examines the current trends in the management of Malignant Melanoma in the E.U. markets under study (France, Germany, Italy, Spain, United Kingdom) from the perspective of medical oncologists (all E.U. markets) and dermatologists (Germany only).
This report series provides the opportunity to gain greater understanding of the changing medical practice patterns in malignant melanoma by dis-ease setting, physicians’ perceptions of brands and specific product attrib-utes and to assess the impact of sales and messaging efforts.

Questions Answered in This Report:

  • Determine the most important issues and unmet needs the treatment of malignant melanoma and how they are being met by the currently available products used by medical oncologists and dermatologists

  • Understand current patient shares in different malignant melanoma treatment settings (adjuvant and unresectable/metastatic settings), as reported by surveyed physicians

  • Understand the differences between medical oncologists’ and derma-tologists’ use of currently available therapies

  • Collect information on the promotional messages and activities target-ing medical oncologists and dermatologists

  • Understand medical oncologists’ and dermatologists’ perceptions of currently available therapies, the current and future competitive land-scape by setting

  • Capture interest and anticipated value of new therapies in develop-ment for malignant melanoma

  • Understand the expected use of emerging therapies and the threats these emerging therapies pose to currently available treatments


Sample Frame & Methodology:

- 252 medical oncologists (EU5) and 68 dermatologists (Germany, Italy, Spain) complete a 45-minute online quantitative survey with several open-ended questions for qualitative feedback.

To qualify, respodents must meet the following criteria:

- Minimum of 10 malignant melanoma patients under their personal management per month

- Have been in practice for a minimum of 2 years and a maximum of 30 years

- More than 75 percent of professional time spent in clinical practice (academic hospital setting allowed 50 percent practice time)


- Final report in PowerPoint format

- Access to author

Key Drugs Covered:

- Cobimetinib, Intron-A, MEK162, Mekinist, MK-3475, nivolumab, Taf-inlar, Temodar, TVec, Yervoy, Zel-boraf

Report Dates:

- Publish: November 2013

Physician Research:

- Medical oncologists

- Dermatologists


- EU5 (France, Germany, Italy, Spain, United Kingdom)

Key Companies Mentioned:

- Amgen

- Bristol-Myers Squibb

- Chugai

- Daiichi Sankyo

- Genentech

- Merck & Co

- Novartis

- Roche

Content Highlights:

- Updates: Key Market Events

- Current Therapies and Medical Practice

- Market Landscape Snapshot

- Product Perceptions

- Unmet Needs

- Emerging Therapies

- Key Competitors

- Detailing Reach and Frequency

- Brand Messages Recall

Related Reports:

- LaunchTrends®: Tafinlar and Mekinist (US)

- TreatmentTrends®: Malignant Melanoma (EU)

- Pharmacor®: Malignant Melanoma

- DecisionBase®: Malignant Melanoma (unresectable)

- PatientBase®: Malignant Melanoma in G7

- Physician and Payer Forum® (US): Cancer Immunotherapeutics

- Physician and Payer Forum® (EU5): Dramatic Changes in the Malignant Melanoma Landscape